Cargando…

Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?

Nearly fifty million older people suffer from neurodegenerative diseases, including Alzheimer (AD) and Parkinson (PD) disease, a global burden expected to triple by 2050. Such an imminent “neurological pandemic” urges the identification of environmental risk factors that are hopefully avoided to fig...

Descripción completa

Detalles Bibliográficos
Autores principales: Giuliano, Sandy, Montemagno, Christopher, Domdom, Marie-Angela, Teisseire, Manon, Brest, Patrick, Klionsky, Daniel J., Hofman, Paul, Pagès, Gilles, Mograbi, Baharia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472882/
https://www.ncbi.nlm.nih.gov/pubmed/37482676
http://dx.doi.org/10.1080/15548627.2023.2214960
_version_ 1785100163934584832
author Giuliano, Sandy
Montemagno, Christopher
Domdom, Marie-Angela
Teisseire, Manon
Brest, Patrick
Klionsky, Daniel J.
Hofman, Paul
Pagès, Gilles
Mograbi, Baharia
author_facet Giuliano, Sandy
Montemagno, Christopher
Domdom, Marie-Angela
Teisseire, Manon
Brest, Patrick
Klionsky, Daniel J.
Hofman, Paul
Pagès, Gilles
Mograbi, Baharia
author_sort Giuliano, Sandy
collection PubMed
description Nearly fifty million older people suffer from neurodegenerative diseases, including Alzheimer (AD) and Parkinson (PD) disease, a global burden expected to triple by 2050. Such an imminent “neurological pandemic” urges the identification of environmental risk factors that are hopefully avoided to fight the disease. In 2022, strong evidence in mouse models incriminated defective lysosomal acidification and impairment of the autophagy pathway as modifiable risk factors for dementia. To date, the most prescribed lysosomotropic drugs are proton pump inhibitors (PPIs), chloroquine (CQ), and the related hydroxychloroquine (HCQ), which belong to the group of disease-modifying antirheumatic drugs (DMARDs). This commentary aims to open the discussion on the possible mechanisms connecting the long-term prescribing of these drugs to the elderly and the incidence of neurodegenerative diseases. Abbreviations: AD: Alzheimer disease; APP-βCTF: amyloid beta precursor protein-C-terminal fragment; BACE1: beta-secretase 1; BBB: brain blood barrier; CHX: Ca(2+)/H(+) exchanger; CMI: cognitive mild impairment; CQ: chloroquine; DMARD: disease-modifying antirheumatic drugs; GBA1: glucosylceramidase beta 1; HCQ: hydroxychloroquine; HPLC: high-performance liquid chromatography; LAMP: lysosomal associated membrane protein; MAPK/JNK: mitogen-activated protein kinase; MAPT: microtubule associated protein tau; MCOLN1/TRPML1: mucolipin TRP cation channel 1; NFE2L2/NRF2: NFE2 like bZIP transcription factor 2; NRBF2: nuclear receptor binding factor 2; PANTHOS: poisonous flower; PD: Parkinson disease; PIK3C3: phosphatIdylinositol 3-kinase catalytic subunit type 3; PPI: proton pump inhibitor; PSEN1: presenilin 1, RUBCN: rubicon autophagy regulator; RUBCNL: rubicon like autophagy enhancer; SQSTM1: sequestosome 1; TMEM175: transmembrane protein 175; TPCN2: two pore segment channel 2; VATPase: vacuolar-type H(+)-translocating ATPase; VPS13C: vacuolar protein sorting ortholog 13 homolog C; VPS35: VPS35 retromer complex component; WDFY3: WD repeat and FYVE domain containing 3; ZFYVE1: zinc finger FYVE-type containing 1.
format Online
Article
Text
id pubmed-10472882
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-104728822023-09-02 Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD? Giuliano, Sandy Montemagno, Christopher Domdom, Marie-Angela Teisseire, Manon Brest, Patrick Klionsky, Daniel J. Hofman, Paul Pagès, Gilles Mograbi, Baharia Autophagy Commentary and Views Nearly fifty million older people suffer from neurodegenerative diseases, including Alzheimer (AD) and Parkinson (PD) disease, a global burden expected to triple by 2050. Such an imminent “neurological pandemic” urges the identification of environmental risk factors that are hopefully avoided to fight the disease. In 2022, strong evidence in mouse models incriminated defective lysosomal acidification and impairment of the autophagy pathway as modifiable risk factors for dementia. To date, the most prescribed lysosomotropic drugs are proton pump inhibitors (PPIs), chloroquine (CQ), and the related hydroxychloroquine (HCQ), which belong to the group of disease-modifying antirheumatic drugs (DMARDs). This commentary aims to open the discussion on the possible mechanisms connecting the long-term prescribing of these drugs to the elderly and the incidence of neurodegenerative diseases. Abbreviations: AD: Alzheimer disease; APP-βCTF: amyloid beta precursor protein-C-terminal fragment; BACE1: beta-secretase 1; BBB: brain blood barrier; CHX: Ca(2+)/H(+) exchanger; CMI: cognitive mild impairment; CQ: chloroquine; DMARD: disease-modifying antirheumatic drugs; GBA1: glucosylceramidase beta 1; HCQ: hydroxychloroquine; HPLC: high-performance liquid chromatography; LAMP: lysosomal associated membrane protein; MAPK/JNK: mitogen-activated protein kinase; MAPT: microtubule associated protein tau; MCOLN1/TRPML1: mucolipin TRP cation channel 1; NFE2L2/NRF2: NFE2 like bZIP transcription factor 2; NRBF2: nuclear receptor binding factor 2; PANTHOS: poisonous flower; PD: Parkinson disease; PIK3C3: phosphatIdylinositol 3-kinase catalytic subunit type 3; PPI: proton pump inhibitor; PSEN1: presenilin 1, RUBCN: rubicon autophagy regulator; RUBCNL: rubicon like autophagy enhancer; SQSTM1: sequestosome 1; TMEM175: transmembrane protein 175; TPCN2: two pore segment channel 2; VATPase: vacuolar-type H(+)-translocating ATPase; VPS13C: vacuolar protein sorting ortholog 13 homolog C; VPS35: VPS35 retromer complex component; WDFY3: WD repeat and FYVE domain containing 3; ZFYVE1: zinc finger FYVE-type containing 1. Taylor & Francis 2023-07-23 /pmc/articles/PMC10472882/ /pubmed/37482676 http://dx.doi.org/10.1080/15548627.2023.2214960 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Commentary and Views
Giuliano, Sandy
Montemagno, Christopher
Domdom, Marie-Angela
Teisseire, Manon
Brest, Patrick
Klionsky, Daniel J.
Hofman, Paul
Pagès, Gilles
Mograbi, Baharia
Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?
title Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?
title_full Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?
title_fullStr Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?
title_full_unstemmed Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?
title_short Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?
title_sort should evidence of an autolysosomal de-acidification defect in alzheimer and parkinson diseases call for caution in prescribing chronic ppi and dmard?
topic Commentary and Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472882/
https://www.ncbi.nlm.nih.gov/pubmed/37482676
http://dx.doi.org/10.1080/15548627.2023.2214960
work_keys_str_mv AT giulianosandy shouldevidenceofanautolysosomaldeacidificationdefectinalzheimerandparkinsondiseasescallforcautioninprescribingchronicppianddmard
AT montemagnochristopher shouldevidenceofanautolysosomaldeacidificationdefectinalzheimerandparkinsondiseasescallforcautioninprescribingchronicppianddmard
AT domdommarieangela shouldevidenceofanautolysosomaldeacidificationdefectinalzheimerandparkinsondiseasescallforcautioninprescribingchronicppianddmard
AT teisseiremanon shouldevidenceofanautolysosomaldeacidificationdefectinalzheimerandparkinsondiseasescallforcautioninprescribingchronicppianddmard
AT brestpatrick shouldevidenceofanautolysosomaldeacidificationdefectinalzheimerandparkinsondiseasescallforcautioninprescribingchronicppianddmard
AT klionskydanielj shouldevidenceofanautolysosomaldeacidificationdefectinalzheimerandparkinsondiseasescallforcautioninprescribingchronicppianddmard
AT hofmanpaul shouldevidenceofanautolysosomaldeacidificationdefectinalzheimerandparkinsondiseasescallforcautioninprescribingchronicppianddmard
AT pagesgilles shouldevidenceofanautolysosomaldeacidificationdefectinalzheimerandparkinsondiseasescallforcautioninprescribingchronicppianddmard
AT mograbibaharia shouldevidenceofanautolysosomaldeacidificationdefectinalzheimerandparkinsondiseasescallforcautioninprescribingchronicppianddmard